Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q4 EPS by 1c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of ($0.55), $0.01 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO